A supplement meant to help joints may be accelerating cognitive decline
For decades, glucosamine has been a quiet fixture of the medicine cabinet — a remedy for aging joints, trusted and unremarkable. Now, researchers at the University of Florida have surfaced a troubling association: the supplement may not be as harmless as assumed, particularly for the millions already navigating the fragile terrain of cognitive decline. A study drawing on over a decade of patient records finds that glucosamine users with mild cognitive impairment were 25% more likely to progress to Alzheimer's, raising the possibility that a routine act of self-care may, for some, be quietly working against them.
- A supplement taken by millions for joint pain has been statistically linked to faster progression from mild cognitive impairment to full Alzheimer's disease — a 25% higher risk that researchers say can no longer be ignored.
- For those already diagnosed with Alzheimer's, taking glucosamine was associated with a 25% increase in mortality risk, turning a commonplace pharmacy purchase into a potential accelerant of decline.
- The suspected mechanism is molecular: glucosamine can cross the blood-brain barrier and appears to amplify an already overactive sugar-tagging process in Alzheimer's brains, disrupting the protein folding that keeps brain cells functioning.
- Mouse models confirmed the pattern — glucosamine worsened memory deficits and increased protein sugar-tagging, while suppressing that process restored memory — and human Alzheimer's brain tissue showed the same elevated signature.
- Researchers stop short of declaring causality, but the clinical urgency is real: roughly seven million Americans with Alzheimer's and millions more with related dementias may be unknowingly compounding their condition with an over-the-counter supplement.
Millions of Americans take glucosamine without much deliberation — a familiar remedy for creaky joints, sold in every pharmacy and endorsed by arthritis organizations. A new study from the University of Florida now complicates that routine. Analyzing more than a decade of patient records using artificial intelligence, researchers found that people taking glucosamine were 25% more likely to progress from mild cognitive impairment to full dementia or Alzheimer's disease. Among those already diagnosed with Alzheimer's, the supplement was linked to a 25% higher mortality risk.
Nearly one in ten patients with cognitive decline in the dataset were taking glucosamine — a proportion that made the association statistically visible. The proposed mechanism centers on what happens when glucosamine crosses the blood-brain barrier. Once inside the brain, it appears to amplify a sugar-tagging process that, in healthy brains, helps proteins fold correctly and reach the right destinations. In Alzheimer's brains, this system is already overactive. Glucosamine, researchers believe, pushes it further.
The theory was tested in genetically modified mice, which showed increased protein sugar-tagging and memory deficits after receiving glucosamine. When the sugar-tagging process was suppressed, memory improved. Human Alzheimer's brain tissue from the university's tissue bank showed the same elevated pattern, lending biological weight to the clinical observation.
Senior researcher Ramon Sun suggested the findings point toward metabolism as an underappreciated driver of Alzheimer's progression — one that existing treatments focused on amyloid plaques and tau tangles may be missing entirely. Biochemist Matt Gentry described the link as an important clinical question now demanding serious attention. The study is careful to frame its findings as an association rather than proven causation, but for the estimated seven million Americans living with Alzheimer's, and the millions more with related dementias, the question has moved well beyond the theoretical.
Millions of Americans reach for glucosamine without much thought—a shelf-stable remedy for creaky knees, endorsed by arthritis foundations, sold in every pharmacy. A new study suggests they may be making a serious mistake. Researchers at the University of Florida have found that people taking glucosamine supplements face a 25% higher risk of progressing from mild cognitive impairment to full dementia and Alzheimer's disease. Among those already diagnosed with Alzheimer's, the supplement was linked to a 25% higher mortality risk.
The finding emerged from an unusual investigation: researchers used artificial intelligence to sift through the University of Florida's medical records spanning 2012 to 2024, searching for patterns among patients with cognitive decline. What they discovered was striking. Nearly one in ten patients with declining brain function were taking glucosamine. When the researchers isolated this group and tracked their outcomes, the association became clear. Those on glucosamine were significantly more likely to cross the threshold from early cognitive problems into full dementia.
Glucosamine itself is straightforward enough. It's a natural compound found in healthy cartilage, the cushioning tissue between joints. The supplement is designed to reduce inflammation in the knee and protect the cells that maintain cartilage structure. Millions of people take it, often for years, with minimal side effects reported. But glucosamine has a property that matters for this story: it can cross the blood-brain barrier, the body's protective filter that controls what enters the brain from the bloodstream. Once there, it appears to cause trouble.
Matt Gentry, chair of biochemistry and molecular biology at the University of Florida, explained the mechanism in plain terms. Proteins are the cell's molecular machines, he said, and many of them require sugar structures attached in precise ways in order to fold correctly, travel to the right location, and perform their function. In a healthy brain, this sugar-tagging system works in balance. In an Alzheimer's brain, something goes wrong. The system becomes overactive. Too many sugar structures get attached. And this excess, rather than helping the brain, appears to drive the disease forward.
The researchers tested this theory in genetically modified mice. When given glucosamine, the mice showed significantly increased sugar attachment to proteins in their cells. They developed memory deficits. But when the researchers suppressed this sugar-tagging process, memory improved. The same pattern showed up in human brain tissue. Researchers examined Alzheimer's brain specimens from the University of Florida's Neuromedicine Brain and Tissue Bank and found the same elevated sugar attachment in those samples.
The mechanism, if confirmed, points to something larger than glucosamine alone. Ramon Sun, senior researcher and director of the Center for Advanced Spatial Biomolecule Research at the University of Florida, framed it this way: altered metabolism appears to be a significant driver of Alzheimer's progression. This suggests that treatments focused solely on the disease's hallmark features—amyloid plaques and tau tangles—may be missing a crucial piece. Addressing the metabolic defect could be essential.
The stakes are substantial. Roughly seven million Americans are living with Alzheimer's disease. Millions more have related dementias like Lewy body or frontotemporal dementia. Many of these people, Sun noted, actively take an over-the-counter supplement that could be accelerating their decline. The study itself is careful about its language—researchers describe the link as an association, not proof of causality. But Gentry called it an important clinical question that now deserves much more attention. For people already struggling with cognitive decline, the question is no longer academic.
Notable Quotes
While it's an association and not proof of causality, it does raise an important clinical question that now deserves much more attention— Matt Gentry, chair of biochemistry and molecular biology at the University of Florida
A lot of these people actively take an over-the-counter supplement that could be making their disease progression worse— Ramon Sun, director of the Center for Advanced Spatial Biomolecule Research at the University of Florida
The Hearth Conversation Another angle on the story
So this is an association, not proof. What's the difference in practical terms for someone taking glucosamine right now?
An association means we've found a pattern—people taking glucosamine tend to progress faster—but we haven't proven glucosamine caused it. Someone else could have taken it. But the lab work with mice and human brain tissue does suggest a plausible mechanism, which makes the pattern harder to dismiss as coincidence.
Why would a supplement designed to help joints affect the brain at all?
Glucosamine is a sugar-related molecule, and it crosses the blood-brain barrier. Once in the brain, it feeds into a system that tags proteins with sugar structures. In Alzheimer's brains, that system is already overactive and malfunctioning. Adding more glucosamine seems to make it worse.
How many people in the study were actually taking glucosamine?
About 8% of the patients with cognitive decline—so roughly one in twelve. It's not a huge number, but it's enough to see a clear pattern when you compare outcomes.
What should someone do if they've been taking it for years?
The study doesn't say. But it raises a question worth discussing with a doctor, especially if someone has cognitive concerns. This isn't definitive proof to stop immediately, but it's evidence enough to warrant a conversation.
Is there any chance this is just correlation—maybe people with early cognitive problems are more likely to take supplements in general?
That's a fair question. The researchers controlled for some variables, but you can't rule out confounding factors in a study like this. That's why they emphasize this deserves more attention and more rigorous research.